» Articles » PMID: 20169081

Mouse Bone Marrow-derived Mesenchymal Stromal Cells Turn Activated Macrophages into a Regulatory-like Profile

Overview
Journal PLoS One
Date 2010 Feb 20
PMID 20169081
Citations 269
Authors
Affiliations
Soon will be listed here.
Abstract

In recent years it has become clear that the therapeutic properties of bone marrow-derived mesenchymal stromal cells (MSC) are related not only to their ability to differentiate into different lineages but also to their capacity to suppress the immune response. We here studied the influence of MSC on macrophage function. Using mouse thioglycolate-elicited peritoneal macrophages (M) stimulated with LPS, we found that MSC markedly suppressed the production of the inflammatory cytokines TNF-alpha, IL-6, IL-12p70 and interferon-gamma while increased the production of IL-10 and IL-12p40. Similar results were observed using supernatants from MSC suggesting that factor(s) constitutively released by MSC are involved. Supporting a role for PGE(2) we observed that acetylsalicylic acid impaired the ability of MSC to inhibit the production of inflammatory cytokines and to stimulate the production of IL-10 by LPS-stimulated M. Moreover, we found that MSC constitutively produce PGE2 at levels able to inhibit the production of TNF-alpha and IL-6 by activated M. MSC also inhibited the up-regulation of CD86 and MHC class II in LPS-stimulated M impairing their ability to activate antigen-specific T CD4+ cells. On the other hand, they stimulated the uptake of apoptotic thymocytes by M. Of note, MSC turned M into cells highly susceptible to infection with the parasite Trypanosoma cruzi increasing more than 5-fold the rate of M infection. Using a model of inflammation triggered by s.c. implantation of glass cylinders, we found that MSC stimulated the recruitment of macrophages which showed a low expression of CD86 and the MHC class II molecule Ia(b) and a high ability to produce IL-10 and IL-12p40, but not IL-12 p70. In summary, our results suggest that MSC switch M into a regulatory profile characterized by a low ability to produce inflammatory cytokines, a high ability to phagocyte apoptotic cells, and a marked increase in their susceptibility to infection by intracellular pathogens.

Citing Articles

Fetal mice dermal mesenchymal stem cells promote wound healing by inducing M2 type macrophage polarization.

Xia Z, Wang Y, Shi N, Lu M, Deng Y, Qi Y World J Stem Cells. 2025; 17(2):101030.

PMID: 40061263 PMC: 11885936. DOI: 10.4252/wjsc.v17.i2.101030.


Preclinical study of engineering MSCs promoting diabetic wound healing and other inflammatory diseases through M2 polarization.

Wu D, Liu R, Cen X, Dong W, Chen Q, Lin J Stem Cell Res Ther. 2025; 16(1):113.

PMID: 40038782 PMC: 11881511. DOI: 10.1186/s13287-025-04248-y.


Mesenchymal Stem Cells and Their Extracellular Vesicles: Therapeutic Mechanisms for Blood-Spinal Cord Barrier Repair Following Spinal Cord Injury.

Nakazaki M, Yokoyama T, Lankford K, Hirota R, Kocsis J, Honmou O Int J Mol Sci. 2025; 25(24.

PMID: 39769223 PMC: 11677717. DOI: 10.3390/ijms252413460.


Innovative Hydrogel Design: Tailoring Immunomodulation for Optimal Chronic Wound Recovery.

Lai C, Chen W, Qin Y, Xu D, Lai Y, He S Adv Sci (Weinh). 2024; 12(2):e2412360.

PMID: 39575827 PMC: 11727140. DOI: 10.1002/advs.202412360.


How to enhance MSCs therapeutic properties? An insight on potentiation methods.

Garcia-Guerrero C, Fuentes P, Araya M, Djouad F, Luz-Crawford P, Vega-Letter A Stem Cell Res Ther. 2024; 15(1):331.

PMID: 39334487 PMC: 11438163. DOI: 10.1186/s13287-024-03935-6.


References
1.
Li Y, Paczesny S, Lauret E, Poirault S, Bordigoni P, Mekhloufi F . Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the Notch pathway. J Immunol. 2008; 180(3):1598-608. DOI: 10.4049/jimmunol.180.3.1598. View

2.
Nauta A, Fibbe W . Immunomodulatory properties of mesenchymal stromal cells. Blood. 2007; 110(10):3499-506. DOI: 10.1182/blood-2007-02-069716. View

3.
Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E . Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood. 2002; 101(9):3722-9. DOI: 10.1182/blood-2002-07-2104. View

4.
Keating A . How do mesenchymal stromal cells suppress T cells?. Cell Stem Cell. 2008; 2(2):106-8. DOI: 10.1016/j.stem.2008.01.007. View

5.
Spaggiari G, Capobianco A, Abdelrazik H, Becchetti F, Mingari M, Moretta L . Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2007; 111(3):1327-33. DOI: 10.1182/blood-2007-02-074997. View